Overview of Ongoing Legal Matters for Investors
Bragar Eagel & Squire, P.C., a prominent law firm specializing in investor rights, wishes to inform shareholders about class action lawsuits that have been initiated against Skye Bioscience, Inc. (NASDAQ: SKYE) and Perrigo Company plc (NYSE: PRGO). These lawsuits present a vital opportunity for investors to advocate for their financial interests and seek justice amidst serious allegations concerning misleading statements and financial discrepancies.
Details Regarding Skye Bioscience, Inc.
Class Period and Important Dates
The class period concerning Skye Bioscience spans from November 4, 2024, to October 3, 2025. Investors looking to assert their rights in this matter need to submit their petitions to the court by the lead plaintiff deadline of January 16, 2026.
Allegations Against Skye Bioscience
During the class period, it is alleged that company executives made false statements about the effectiveness of their treatment, nimacimab. These disclosures indicate that the drug was not as effective as suggested, leading to significant discrepancies in how the company presented its clinical, regulatory, and commercial prospects. On October 6, 2025, Skye released data indicating that the primary endpoint of weight loss compared to placebo was not met, which triggered a substantial decline in stock price.
Perrigo Company plc Details
Key Timeline and Lead Plaintiff Information
The allegations concerning Perrigo span from February 27, 2023, to November 4, 2025. The deadline for potential lead plaintiffs to join the case is also set for January 16, 2026.
Issues Within Perrigo's Financials
Investors allege that during the class period, Perrigo failed to disclose significant underinvestment in its infant formula business acquired from Nestlé, leading to overstated financial results. A disappointing financial update on November 5, 2025, revealed drastic cuts to the fiscal outlook for 2025 due to problems in the infant formula sector, resulting in a significant drop in share price on that day.
What This Means for Investors
As an investor in either Skye Bioscience or Perrigo, it's critical to stay informed about these ongoing lawsuits and understand how they might impact your financial standing. Investors have a chance to step forward and potentially recoup losses resulting from misleading information provided by these companies.
Contact Information for Legal Representation
Bragar Eagel & Squire, P.C. offers expertise in handling securities and investor legal issues. Based in New York, the firm invites investors to learn more about their rights and options. Those interested may reach out via the following:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Melissa Fortunato, Esq.
(212) 355-4648
investigations@bespc.com
www.bespc.com
Frequently Asked Questions
What are the class action lawsuits about?
The lawsuits are aimed at addressing misleading statements made by Skye Bioscience and Perrigo, which allegedly harmed investors.
Who can join the class actions?
Shareholders of Skye Bioscience and Perrigo during the respective class periods are eligible to join the lawsuits.
What are the deadlines for filing?
Both class actions have a lead plaintiff deadline of January 16, 2026, for those wishing to take a more active role.
How can investors get more information?
Investors can acquire more information through Bragar Eagel & Squire, P.C.'s resources and by visiting their official website.
What should I do if I believe I am affected?
If you believe you have been impacted, it is recommended to consult with a legal expert or the law firm for personalized guidance regarding your circumstances.